In a landmark advancement for solid tumor treatment, CARsgen Therapeutics’ CLDN18.2-targeted CAR-T therapy, satri-cel (CT041), has achieved 96.1% disease control rate (DCR) in advanced gastric cancer patients, with plans for a 2025 commercial launch in China. The therapy, recently granted Breakthrough Therapy Designation by China’s NMPA, could become the world’s first approved CAR-T treatment for solid tumors.
Key Highlights:
- Unprecedented Efficacy: In a Phase II trial, CT041 demonstrated 54.9% objective response rate (ORR) and 96.1% DCR in gastric/esophagogastric junction adenocarcinoma patients, with median survival (9.0 months OS) doubling versus standard care.
- Global First: As the first CLDN18.2-targeted CAR-T, CT041 has received FDA Orphan Drug, EMA PRIME, and RMAT designations, underscoring its potential for gastric, pancreatic, and other CLDN18.2-positive cancers.
- Path to Approval: CARsgen plans to submit NDA to China’s NMPA in H1 2025, following Phase II success. Published results in Nature Medicine (June 2024) confirm durable responses, including 13.1-month survival in high-expression subgroups.
- Patient Impact: “CT041 could redefine treatment for refractory gastric cancer,” said Prof. Lin Shen of Peking University Cancer Hospital, noting its “manageable safety and tumor-shrinking power” in metastatic cases.
Background:
CLDN18.2, a protein overexpressed in 80% of GI adenocarcinomas, emerged as a “golden target” after decades of limited progress in gastric cancer therapy. CT041’s autologous CAR-T approach leverages engineered immune cells to attack tumors while sparing healthy tissue—a feat previously elusive in solid tumors.
Trials & Milestones:
- Phase I (2019–2022): 98 patients showed 38.8% ORR, 91.8% DCR; subset analyses revealed 8.4-month PFS in responders.
- Global Recognition: FDA/EMA fast-tracked CT041 after early data showed complete responses in pancreatic cancer (published Journal of Hematology & Oncology, 2023).
Next Steps:
CARsgen is accelerating production for post-approval access, with trials expanding to pancreatic and ovarian cancers. Eligible patients can enroll via clinicaltrials.gov (NCT04581473).
Quote from Dr. Zonghai Li, CARsgen Founder:
“This is a turning point for patients with no options left. We’re committed to delivering CT041 rapidly—and exploring its full potential across CLDN18.2-positive cancers.”
Reference
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
